Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
VELTRA, 3.7 times Increase in Ordinary Profit for The Current Fiscal Year
7048 VELTRA Corporation 【J-GAAP】
Earnings ReportVELTRA Corporation <7048> [TSE Growth] announced its financial results after the market closed on February 13th (15:31). The consolidated ordinary profit/loss for the fiscal year ended December 2025 turned into a profit of 99 million yen (compared to a loss of 298 million yen in the previous period). For the fiscal year ending December 2026, the consolidated ordinary profit is expected to surge 3.7 times the previous term, reaching 366 million yen.
In the most recent three-month period, from October to December (4Q), the consolidated ordinary profit significantly dropped to 12 million yen, a 66.7% decrease compared to the same period last year. The operating profit margin drastically worsened from 6.1% in the same period last year to 1.1%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 3,123 | -67 | -112 | -57 | -1.6 | 0 | Feb 14, 2024 | J-GAAP |
| Dec, 2024 | 4,304 | -175 | -298 | -407 | -11.2 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 4,581 | 105 | 99 | 140 | 3.8 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | +6.4% | - | - | - | - |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Guidance | 4,500 | 120 | 110 | 100 | 2.7 | 0 | Nov 14, 2025 | J-GAAP |
| Dec, 2025 Results | 4,581 | 105 | 99 | 140 | 3.8 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | +1.8% | -12.5% | -10.0% | +40.0% | +40.7% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 2,101 | -89 | -104 | -79 | -2.2 | 0 | Aug 14, 2025 | J-GAAP |
| Jan - Jun, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2024 | 4,304 | -175 | -298 | -407 | -11.2 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 4,581 | 105 | 99 | 140 | 3.8 | 0 | Feb 13, 2026 | J-GAAP |
| Dec, 2026 Guidance | 5,000 | 380 | 366 | 340 | 9.3 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | +9.1% | +261.9% | +269.7% | +142.9% | +141.9% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 1,103 | 67 | 36 | -88 | -2.4 | 6.1 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 1,131 | 56 | 36 | 27 | 0.8 | 5.0 | May 14, 2025 | J-GAAP |
| Apr - Jun, 2025 | 970 | -145 | -140 | -106 | -2.9 | -14.9 | Aug 14, 2025 | J-GAAP |
| Jul - Sep, 2025 | 1,337 | 181 | 191 | 165 | 4.5 | 13.5 | Nov 14, 2025 | J-GAAP |
| Oct - Dec, 2025 | 1,143 | 13 | 12 | 54 | 1.5 | 1.1 | Feb 13, 2026 | J-GAAP |
| YoY | +3.6% | -80.6% | -66.7% | - | - |
Related Articles
Future Innovation Group, 21% Increase in Ordinary Profit, Record High for The First Time in Four Years
TAIKO PHARMA, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 8% Increase in The Current Fiscal Year, Resuming Dividends at 3.3 Yen for the First Time in five terms., This Fiscal Year to Increase Dividend by 0.2 Yen
MS&AD Insurance, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 7%, Exceeds Full-Year Plan
Neural Group, Last Fiscal Year's Ordinary Profit Turns to Loss, Current period performance is undisclosed.
BrightPath Biotherapeutics, Apr-Dec (Cumulative 3Q) Net Income Loss Widens, Oct-Dec Net Income Loss Widens
Dynamic Map, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Widens, Oct-Dec Ordinary Profit Loss Widens
LIFE CREATE, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 41% Decrease
Asia Air Survey, Oct-Dec (1Q) Operating Profit Turns to Profit
Solvvy, First Half Ordinary Profit Increases by 22%, Oct-Dec Ordinary Profit Increases by 77%
OPTIMUS GROUP, Undisclosed Pretax Income to Reach 5.9 Billion Yen for The Current Fiscal Year